Calprotectin in Cystic Fibrosis by Nisreen Rumman et al.
Rumman et al. BMC Pediatrics 2014, 14:133
http://www.biomedcentral.com/1471-2431/14/133RESEARCH ARTICLE Open AccessCalprotectin in Cystic Fibrosis
Nisreen Rumman1,3*, Mutaz Sultan2,3, Khalil El-Chammas2,5, Vi Goh2,4, Nita Salzman2, Diana Quintero1 and Steven Werlin2Abstract
Background: There is increasing evidence that intestinal inflammation plays a major role in gastrointestinal
symptoms in cystic fibrosis (CF). Fecal calprotectin is a marker that is elevated in several gastrointestinal
inflammatory diseases, but little is known about its value in CF. We aimed to look for associations of elevated fecal
calprotectin among CF patients and whether its level correlates with the clinical manifestations of CF.
Methods: A single stool specimen was collected from 62 patients with CF. Fecal calprotectin was measured using the
commercially available ELISA kits (PhiCal™ test). Clinical data were collected from patients’ records and CF registry.
Results: There were no significant differences between CF patients with normal and abnormal fecal calprotectin levels.
However, patients who were not receiving inhaled antibiotics had higher fecal calprotectin levels than those who were.
Conclusion: Elevated fecal calprotectin may not accurately predict intestinal inflammation in CF. However, the fact that
it was elevated in both pancreatic sufficient and insufficient groups supports the concept of “cystic fibrosis
enteropathy” regardless of the pancreatic status.Background
Cystic fibrosis (CF) is the most common cause of pancre-
atic insufficiency (PI) in children. Between 85% - 90% of
CF patients have PI and malabsorption. These patients are
typically treated with pancreatic enzyme replacement ther-
apy (PERT). However, CF patients with pancreatic suffi-
ciency (PS), and patients with PI who receive adequate
PERT, may have persistent abdominal symptoms. It has
been suggested that other poorly understood non pancre-
atic confounding factors are likely contributors [1].
There is no specific noninvasive test to prove the pres-
ence of intestinal inflammation. Several studies have
shown evidence of intestinal inflammation in CF. In-
creased amounts of inflammatory markers were found in
whole gut lavage indicating immune activation in the
intestinal mucosa of CF patients [2-4]. A study using wire-
less capsule endoscopy (WCE) showed varying degrees of
inflammatory findings including edema, mucosal breaks
and ulcerations in most adult patients with CF [5].
Calprotectin, a protein found mainly in neutrophils,
but also in monocytes and macrophages, is released dur-
ing neutrophil activation or death. Calprotectin can be* Correspondence: rummannisreen@hotmail.com
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unless otherwise stated.measured in plasma as well as other body fluids but is
six times more concentrated in feces than in blood [6,7].
Fecal calprotectin (FC) is thus an inflammatory marker
that is elevated in a variety of inflammatory intestinal
diseases such as Crohn’s disease and CF [5,7,8]. Canani
et al. showed a correlation between FC with the histo-
logic grade of mucosal inflammation observed at endos-
copy in patients with inflammatory bowel disease (IBD).
In their study FC was a more accurate predictor of active
mucosal inflammation than clinical scores and serum
markers [8]. Similarly, Bruzesse et al. showed that intes-
tinal mucosal inflammation is a major feature of cystic
fibrosis. A comparison of 30 CF patients and 15 IBD pa-
tients with 30 healthy controls showed that the first 2
groups had significantly higher mean FC than controls [9].
The present study was performed to determine the fre-
quency of elevated FC in CF patients, and to determine
whether there are any associations with different charac-
teristics such as pancreatic status, gastrointestinal morbid-
ities, pulmonary function tests (PFTs) and pulmonary
exacerbations. We also evaluated whether FC values differ
between patients who receive certain treatments (PERT,
probiotics and antibiotics) and those who do not.Methods
Between January 2009 – November 2010 all patients at-
tending the CF clinic at the Children’s Hospital ofal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Study population
Factors N Median (range)
Fecal calprotectin (mcg/gm) 59 94.29 (10–200)
Age at sample collection (yrs) 59 0.67 (0.04-4.58)
Age at diagnosis (yrs) 59 0 (0–2.17)
FVC (%) 44 100 (53–147)
FEV1 (%) 44 93.5 (25–139)
FEF25 (%) 44 85 (6–170)
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for the study at their next clinic visit regardless of their
age, CF mutations, pancreatic status or severity of dis-
ease. Sixty two patients participated. The samples were
stored at (−600C) until analysis. FC is stable at room
temperature for up to 1 week [8,10,11].
Clinical data were collected from patients’ medical re-
cords and CF registry. Data collected included: age at CF
diagnosis (years); age at sample collection (years); spir-
ometry parameters including forced vital capacity (FVC),
forced expiratory volume in 1 second (FEV1) and forced
expiratory flow 25%-75% (FEF25-75%); gender; ethnicity;
diagnosis (classic CF, or CF related metabolic syndrome
- CRMS); body mass index (normal, obese, overweight);
symptoms (abdominal pain, gas, vomiting, fever, pul-
monary exacerbation); stool characteristics (frequency,
consistency); hospitalizations; morbidities (meconium
ileus, surgery, bowel resection, distal intestinal obstruc-
tion syndrome (DIOS); antibiotic use (inhaled, intraven-
ous, oral); pancreatic enzyme supplementation; probiotic
use; and pancreatic function (PI versus PS ).
Calprotectin assay
The coded stool samples were thawed, aliquots of
80–120 mg were taken and then a quantitative measure-
ment was done using commercially available ELISA kits
(PhiCal™ test). ELISA steps were all completed according
to the instructions of the manufacturer.
This study was approved by the institutional review
board of the Children’s Hospital of Wisconsin and con-
sent and/or assent was obtained from patients and/or
parents as appropriate.
Statistics
Descriptive statistics were used to summarize the sam-
ple’s characteristics. Chi square and Fisher’s exact test
were used to assess demographic differences. Bivariate
analysis was used to examine the effect of certain pa-
tient’s characteristics (use of inhaled, intravenous, or
oral antibiotics), and FEV1 (normal being equal to or
greater than 80% predicted) on FC levels. Analyses were
performed for a normal FC level defined as less than
50 mcg/gm.
A statistical significance (alpha) level of 0.05 was used
throughout, and SAS On Demand Enterprise Guide
4.2 (SAS Institute, Cary, NC) was used to perform all
statistical analysis.
Results
A total of 62 patients participated in the study. Three
were excluded because of incomplete data. Data of 59
patients (33 females, 26 males) were analyzed. Forty
three patients were PI and 16 patients were PS. Fifteen
patients were < 6 years of age. In our clinic patients lessthan 6 years of age do not routinely perform PFTs. PFTs
were available for 44 patients.
Patient characteristics
The median patient age was 8 years. The median FC
level was 94 mcg/gm (Table 1). There were no signifi-
cant differences with respect to age at CF diagnosis, age
at sample collection, and spirometry parameters between
patients with normal and abnormal FC levels (Table 2).
There was no statistically significant difference in FC
levels between patients in regards to the other character-
istics studied including gender, ethnicity, growth param-
eters, genotype, gastrointestinal symptoms (abdominal
pain, distention/gas, vomiting, and stool pattern), being
on PERT and/or probiotics, history of meconium ileus,
bowel surgery/resection, history of distal intestinal ob-
struction syndrome (DIOS), number of pulmonary exac-
erbations and hospitalizations (Table 3). However, there
was a significant statistical difference in regards to the
use of inhaled antibiotics; those who were not on inhaled
antibiotics had higher odds of having abnormal FC levels
higher than 50 mcg/gm (p value 0.0101) (Table 4).
Bivariate analysis
Results of the bivariate analysis are summarized in Tables 4
and 5. The only significant finding was that patients with
a normal FC level compared to those with levels above 50
mcg/gm, had higher odds of being on antibiotics (inhaled,
intravenous, or oral).
Discussion
The evidence that factors other than PI and malabsorp-
tion play a role in “CF enteropathy” is increasing
[2,5,9,12,13]. Intestinal inflammation may be one of the
factors that result in persistence of GI symptoms even in
the patients who are PS or PI patients receiving ad-
equate PERT.
In the CF lung, there is still controversy whether inflam-
mation precedes or follows infection. While Armstrong
et al. found that inflammation follows respiratory infec-
tions [14,15], other studies of broncho-alveolar lavage
fluid in infants with CF found elevated inflammatory
markers early in the course of the disease even in the
Table 2 Pulmonary function test characteristics
Factors Normal Abnormal P-value
N Median N Median
Age at diagnosis (yrs) 18 0.04 41 0 0.9718
Age at sample (yrs) 18 6.00 41 9.00 0.1956
FVC (%) 15 105.00 29 99.00 0.3040
FEV1 (%) 15 106.00 29 92.00 0.3040
FEF25 (%) 15 92.00 29 84.00 0.5858
Rumman et al. BMC Pediatrics 2014, 14:133 Page 3 of 7
http://www.biomedcentral.com/1471-2431/14/133absence of bacterial colonization or infection [16,17]. This
suggests that inflammation might be the earliest event in
the CF lung causing damage and thus predisposing to in-
fection, and that the basic defect in cystic fibrosis trans-
membrane regulator (CFTR) itself may initiate or amplify
inflammation.
As with the lungs, the CFTR expression is high in the
intestines. Dysregulation of the inflammatory response is
thought to be present in tissues that express CFTR [2].
This could explain why PERT treatment does not com-
pletely correct gastrointestinal symptoms and why pa-
tients with PS may still have gastrointestinal symptoms.
Bruzzese et al. showed that probiotics reduce intestinal
inflammation and decrease pulmonary exacerbations
and hospital admissions in patients with CF, this indi-
cates that there may be a relationship between pulmon-
ary and intestinal inflammation in CF [18].
Intestinal inflammation is a typical feature in CF [13].
This may be related to several other factors in addition
to a dysregulated inflammatory response associated with
the basic cellular defect of CFTR [2]. High doses of
PERT can cause inflammation and fibrosing colonopathy
[19]. Multiple factors predispose CF patients to small in-
testinal bacterial overgrowth (SIBO) which can cause in-
flammation, mucosal damage and maldigestion [1,18].
A local intestinal mucosal defect, believed to be present
in CF patients, may explain the increased permeability
to sugars and the disacchariduria that characterizes CF
patients [20].
The gold standard for the detection of intestinal mu-
cosal inflammation is endoscopy and biopsy, which are
invasive and expensive. There is no other specific nonin-
vasive test to accurately detect intestinal inflammation.
But, based on previous studies correlating FC levels with
the severity of inflammation in other inflammatory con-
ditions, mainly inflammatory bowel disease (IBD), we
looked for evidence of intestinal inflammation in CF pa-
tients by measuring FC [8,10,11].
FC in CF has been previously evaluated in 2 studies.
Bruzzese et al. found that FC was elevated in 27 of 30
pediatric CF patients [9]. In 10 patients FC normalized
after treatment with a probiotic, lactobacillus GG (LGG),
suggesting the possibility of bacterial overgrowth. In thesame study rectal nitric oxide (NO) production, another
non invasive marker of intestinal inflammation that is ele-
vated in the stool of children with active IBD was in-
creased, thus supporting the FC results. NO production
also decreased after LGG [9]. In the second study, FC was
measured along with wireless capsule endoscopy (WCE)
to quantify and localize intestinal inflammation in patients
with CF and relate these findings to the clinical status and
pancreatic phenotype [5]. The images showed generalized
enteropathy unrelated to pancreatic function status. FC
was measured in 30 patients. It was normal (<50 mcg/gm)
in all 9 PS patients as well as in all patients in the control
group, but elevated in 18/21 of the PI patients indicating
intestinal inflammation only in the patients with PI [5].
We decided to identify the role of calprotectin in our
CF population. In contrast to the described studies, we
found that 10/16 PS patients had elevated FC levels
comparable to those of PI patients. Since FC is a meas-
ure of inflammation, this indicates that intestinal inflam-
mation is also present in PS patients and implies that
inflammation is part of the disease process in CF regard-
less of the pancreatic status and is not related to PERT.
In the present study there was no correlation between
FC and any of the characteristics studied nor was there a
difference in FC levels between PI and PS patients. Only
19 patients in our study (6/16 PS and 13/43 PI) had
levels < 50 mcg/gm. This finding supports the concept
of “CF enteropathy” as an independent entity in the dis-
ease process.
Pulmonary function tests were available for 44 patients.
Patients with lower FEV1 were more likely to have higher
FC levels; however this was not statistically significant.
Lower FEV1 indicates worse pulmonary status, and hence
probably more sputum production which if swallowed
could contribute to increased intestinal inflammation. Ex-
cluding the sputum from the GI tract is impossible since
the muco-ciliary escalator cannot be turned off in vivo
[2,12]. Bacteria and other contents of swallowed sputum
might be involved in direct stimulation of the intestinal
mucosa. Calprotectin in the sputum itself might also in-
crease the fecal levels. Golden et al. studied plasma calpro-
tectin levels as a marker of pulmonary inflammation in
CF. They found that plasma calprotectin was significantly
higher in CF patients compared to matched controls [21].
Both sputum and serum calprotectin significantly de-
creased following treatment of a pulmonary exacerbation
in a study by Gray et al. [22]. In our study, there was no
significant difference in FC levels between patients who
had a pulmonary exacerbation within one month prior to
sample collection and those who had no recent exacerba-
tions. The patients who were receiving inhaled antibiotics
had significantly lower FC levels. But this was not true for
oral or intravenous antibiotic usage (within one month
prior to sample collection).
Table 3 Patient characteristics
Factors N Normal FC (%) Abnormal FC (%) P-value
Gender 1.0000
Female 33 30 70
Male 26 31 69
Ethnicity 0.3778
American Indian 1 100 0
Black 2 0 100
White 50 32 68
Hispanic 2 50 50
Mixed 1 0 100
Other 3 0 100
Diagnosis 0.6639
Classic CF (PI and PS) 52 29 71
CRMS 7 43 57
Symptoms
Abdominal pain 1.0000
No 51 31 67
Yes 8 25 75
Gas 0.2181
No 56 29 71
Yes 3 67 33
Vomiting 0.3027
No 55 33 67
Yes 4 0 100
Fever
No 59 31 69
Yes 0 0 0
Exacerbation 0.7748
No 37 32 68
Yes 22 27 78
Stool frequency 0.6274
1 16 31 69
1 or 2 7 14 86
1 or 3 1 0 100
2 17 24 76
2 or 3 5 40 60
2 or 4 1 100 0
3 4 25 75
3 or 4 4 50 50
4 2 50 50
5 or 6 1 100 0
7 or 8 1 0 100
Stool description 0.6394
Formed 47 32 68
Formed foul 1 0 100
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Table 3 Patient characteristics (Continued)
Formed greasy 1 0 100
Foul greasy 1 100 0
Loose 5 40 60
Loose formed 2 0 100
Loose foul 1 0 100
Soft 1 0 100
Hospitalization 0.7187
0 33 27 73
1 9 33 67
2 5 20 80
3 7 57 43
4 3 33 67
7 1 0 100
10 1 0 100
Meconium Ileus 0.7659
No 40 33 68
Yes 19 26 74
Surgery 1.0000
No 40 30 70
Yes 19 32 68
Intestinal resection 1.0000
No 51 31 69
Yes 8 25 75
Distal intestinal obstruction syndrome 1.0000
No 58 31 70
Yes 1 0 100
Inhaled antibiotics 0.0101
No 35 17 83
Yes 24 50 50
IV antibiotics 0.1604
No 54 28 72
Yes 5 60 40
Oral antibiotics 0.0880
No 31 19 81
Yes 28 43 57
Pancreatic enzyme 0.7533
No 16 25 75
Yes 43 33 67
Probiotic 0.0894
No 57 28 72
Yes 2 100 0
Pancreatic status 0.3433
Insufficient 43 35 65
Sufficient 16 19 81
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Table 4 Bivariate analysis of antibiotic use and fecal
calprotectin (using normal cut off for fecal calprotectin
of <50 Mcg/Gm)
% OR 95% CI P-value
Inhaled 0.0101
Normal 67 R
Abnormal 29 0.21 0.06, 0.68
IV 0.1604
Normal 17 R
Abnormal 5 0.26 0.04, 1.69
Oral 0.0880
Normal 67 R
Abnormal 39 0.32 0.1, 1.02
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for inflammation and thus elevated FC levels. CF pa-
tients have multiple risk factors for small intestinal bac-
terial overgrowth (SIBO) including inspissated intestinal
secretions, constipation, slow intestinal motility and fre-
quent courses of antibiotics [23]. The frequent use of
acid blockers, particularly proton pump inhibitors, in CF
patients is another trigger for SIBO [23]. Lisowska et al.
studied evidence of SIBO in 25 CF patients using the
hydrogen-methane breath test, and at the same time
measured the FC levels in those patients [24]. They
found similar FC levels in both SIBO positive and nega-
tive patients, concluding that SIBO does not correlate
with intestinal inflammation in CF. We did not assess
our patients for SIBO.
We are aware that our study had several limitations: It
is a small study at only one CF center, there was no con-
trol group and only one sample was obtained. Larger
multicenter prospective studies may help determine if
serial and longitudinal calprotectin levels may have clin-
ical relevance during symptomatic episodes and whether
certain interventions will have an impact on these levels.
However, the finding of abnormal calprotectin levels in
the pediatric population brings up the question about
early detection of CF enteropathy. In addition, our ob-
servation of lower levels of calprotectin in individuals on
inhaled steroids may prove that bacterial control in the
intestinal tract may be also beneficial.Table 5 Bivariate analysis of FEV1 and fecal calprotectin
(using normal cut off for fecal Calprotectin of
<50 mcg/gm)
% OR 95% CI p-value
FEV1 0.4884
Normal 20 R
Abnormal 34 2.11 0.48, 9.24Conclusion
There is increasing evidence that intestinal inflammation
is part of the disease in CF patients. The causes of this
inflammation may be multifactorial, and could be con-
tributing to the gastrointestinal symptoms in PS patients
and PI patients receiving apparently adequate PERT. FC
is used as a marker of inflammation and although it may
not be as an accurate indicator of intestinal inflamma-
tion in CF as it is in other inflammatory conditions of
the intestines the fact that it was elevated in both PS
and PI groups supports the concept of “CF enteropathy”
regardless of the pancreatic status. This study highlights
the limitation of an increasingly popular test as a marker
of intestinal inflammation in the CF population. How-
ever, a larger cohort of patients is needed to confirm
these findings.
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